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Abstract Myosin light chain kinase (MLCK) is the key
regulator of cell motility and smooth muscle contraction in
higher vertebrates. We searched for the features of the high
molecular weight MLCK (MLCK-210) associated with its
unique N-terminal sequence not found in a more ubiquitous
lower molecular weight MLCK (MLCK-108). MLCK-210
demonstrates stronger association with the Triton-insoluble
cytoskeletons than MLCK-108, suggesting the role for this
sequence in subcellular targeting. Indeed, the expressed unique
domain of MLCK-210 binds and bundles F-actin in vitro and
colocalises with the microfilaments in transfected cells reprodu-
cing endogenous MLCK-210 distribution. Thus, MLCK-210
features an extensive actin binding interface and, perhaps, acts as
an actin cytoskeleton stabiliser.
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1. Introduction
A prerequisite for vertebrate smooth muscle contraction
and various non-muscle motile events in response to intracel-
lular Ca2 signalling is the phosphorylation of myosin II reg-
ulatory light chain (RLC) at Ser-19 by a calmodulin (CaM)-
regulated protein kinase, myosin light chain kinase (MLCK).
The phosphorylation of RLC enhances the Mg2-ATPase ac-
tivity of myosin, which catalyses cyclic conversion of ATP
chemical energy into mechanical work through the reversible
actomyosin interactions. The molecular mechanism for trans-
duction of a Ca2 signal into muscle contraction and cell
motility changes via the CaM/MLCK-regulated pathway is
one of the most extensively characterised signal transduction
systems in cell biology, evolving from years of investigation by
a number of di¡erent groups (for review, see [1,2]).
It is now established that vertebrate MLCK is encoded by a
single gene locus that produces two size classes of the enzyme
with computed masses of about 108 000 and 210 000 (further
referred to as MLCK-108 and MLCK-210). MLCK isoforms
are di¡erentially expressed in smooth muscle and non-muscle
tissues and during embryonic development [3,4]. Both
MLCK-210 and MLCK-108 use a common set of exons to
encode the catalytic and kinase-related protein (KRP) seg-
ments that are characteristic of most vertebrate MLCKs. Re-
cent reports [5,6] suggest that in mammals, both size classes of
MLCK may include multiple splice variants, adding further
complexity to the system.
The molecular di¡erence between MLCK-210 and MLCK-
108 is the presence of an extended amino-terminal tail region
in the former isoform. This unique domain has sequence mo-
tifs (e.g. six immunoglobulin C2-type-related folds [3,6]) char-
acteristic of proteins involved in extended protein-protein in-
teractions, including those that interact with actomyosin.
Here, we present evidence that the unique sequence of
MLCK-210 is, indeed, involved in the interaction of this kin-
ase isoform with the micro¢laments and contributes to its
tighter, than MLCK-108, association with the actin cytoskel-
eton.
2. Materials and methods
2.1. Materials
General reagents of analytical and molecular biology grade were
from Sigma and Fisher Scienti¢c. Monoclonal antibody that recog-
nises both MLCK-108 and MLCK-210 (clone K-36) was from Sigma.
2.2. Antibody production and immunoblots
Rabbit polyclonal antibodies #859 that recognise both MLCK-210
and MLCK-108 [7], #3007 against KRP domain of MLCK [3] and
#3528 against a peptide antigen corresponding to amino acid residues
306^321 of chicken MLCK-210 [3] have been described. Mouse
monoclonal antibody 2F4 was produced to the same synthetic peptide
as in [3]. 2F4 monoclonal antibody belongs to the IgG1 subtype and
recognises MLCK-210 in chicken aortic smooth muscle cells (Fig. 1).
Immunoblots were developed using either enhanced chemilumines-
cence (ECL) (Phototope-HRP, NEB) or 3,3P-diaminobenzidine. HP-
IIcx scanner and NIH Image software were used to quantitate stained
gels and immunoblots.
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2.3. Protein puri¢cation and analysis
MLCK-210 was puri¢ed from adult chicken aorta. Brie£y, the tis-
sue was homogenised at 4‡C and extracted with bu¡er E (20 mM
MOPS, pH 7.4, 2 mM EGTA, 5 mM DTT, 10 mM benzamidine,
0.1 mM N-p-tosyl-L-lysine chloromethyl ketone (TLCK), 0.05 mM
N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), 1 mM phenyl-
methylsulfonyl£uoride (PMSF)) containing 400 mM NaCl, 30 mM
MgCl2 and 0.02 mg/ml aprotinin. Clari¢ed extract was diluted 10-
fold with bu¡er E and applied onto a 1 ml DE-52 (Whatman) column.
Concentrated crude MLCK-210 was step-eluted with bu¡er E con-
taining 240 mM NaCl and the concentration of NaCl in eluate was
adjusted to 0.5 M. MLCK-210 was ¢nally a⁄nity-puri¢ed on #3528
antibody coupled to protein A-Sepharose CL-4B (Pharmacia Bio-
tech). After washing the column with the 1 M NaCl-containing bu¡er
E, MLCK-210 was eluted with 0.2 M glycine, pH 2.2, 0.5 M NaCl,
1 mM DTT, 0.2 mM PMSF and neutralised immediately with 2 M
Tris-HCl, pH 8.0. No MLCK-108 contamination was detected in
MLCK-210 preparation. MLCK-210 was quantitated by immuno-
blotting using K-36 monoclonal antibody and turkey MLCK-108 as
a standard. Based on the primary structure information [3], the as-
sumption was made that both MLCK isoforms are equally stained by
K-36 antibody.
MLCK-210 catalytic activity was measured according to [8] and
was shown to be Ca2-CaM-dependent. MLCK-210 had a speci¢c
activity of 0.7 and 0.8 Wmol Pi/min/mg with heavy meromyosin
(HMM) and RLC as substrates, respectively. Speci¢c activity of
chicken gizzard MLCK-108 towards RLC was 1.6 Wmol Pi/min/mg
under the same conditions. Like MLCK-108, MLCK-210 phosphoryl-
ated the same peptide as revealed by 1-D tryptic phosphopeptide
mapping [9] and conferred to smooth muscle myosin (SMM) the
ability to support actin ¢lament movement in an in vitro motility
assay (data not shown).
Rabbit skeletal actin [10], turkey gizzard MLCK-108 [11], unphos-
phorylated chicken gizzard myosin [8] and HMM [12] were prepared
as described. The protein concentration was determined spectrophoto-
metrically using the following extinction coe⁄cients and molecular
masses: SMM, A1%280 nm = 5.6, 500 kDa; HMM, A
1%
280 nm = 6.5, 330
kDa; G-actin, A1%290 nm = 6.1, 43 kDa.
Sedimentation analysis was performed as described [13] but in the
presence of 100 mM NaCl. Low speed centrifugation was conducted
at 12 000Ug for 30 min at 4‡C. For electron microscopy [13], protein
solution was diluted immediately before the application on the grids
with an ice-cold bu¡er to achieve the ¢nal actin concentration 0.1 mg/
ml.
2.4. Plasmid construction and expression
The 7n-32-R clone in phage Vgt 11 [3] was used as an initial tem-
plate to design N934 construct containing the unique sequence of
MLCK-210 (amino acids 1^934). PCR was performed using Pfu
DNA polymerase, 5P-primer 5P-AAAGATCTCATGGGGGATGT-
TAAAC-3P containing the BglII restriction site (underlined) and 3P-
primer 5P-TTGGATCCTATTGCTCGGCTGGG-3P which included
stop codon and the BamHI restriction site (underlined). The PCR
product was subcloned into pET-30c(+) vector (Novagen). N934
was expressed in BL21(DE3) pLys Escherichia coli strain as a fusion
protein containing N-terminal 6UHis-tag and S-tag and puri¢ed us-
ing Ni-NTA metal-chelate chromatography (Qiagen).
For the transient expression in cultured cells, the N934 DNA se-
quence was subcloned into the pFLAG CMV2 vector (Kodak) at the
BglII and BamHI restriction sites to provide expression of N934 with
the FLAG sequence and nine additional amino acids (Leu-Ala-Ala-
Ala-Asn-Ser-Ser-Ile-Asp) at the N-terminus.
MLCK-210-green £uorescent protein (GFP) construct in pEGFP
vector (Clontech) was designed using the MLCK-210 clone described
in [3] and kindly provided by Dr Anne Bresnick (Albert Einstein
College of Medicine, Bronx, NY, USA).
2.5. Cell culture and manipulation
Primary cells from chicken embryo aorta (day 19) were prepared by
0.25% trypsin dissociation. These cells, HeLa cells (ATCC# CCL-2)
and A10 cells (ATCC# CRL-1476) were cultured in DMEM supple-
mented with 10% FBS (HyClone). For immuno£uorescence micros-
copy, cells were ¢xed in 3.7% formaldehyde and permeabilised with
1% Triton X-100. F-actin was visualised using TRITC-phalloidin (Sig-
ma). Mouse monoclonal antibody to FLAG (Kodak) and FITC-la-
belled anti-mouse secondary antibodies (Sigma) were used. Cells were
examined using Zeiss Photomicroscope III and photographed on Ko-
dak Tri X-pro 400 ¢lm.
HeLa cells at 50^70% con£uence were transfected using the Max-
ifectin-21 kit (Pepline, Moscow, Russia) according to the manufactur-
er’s protocol and after 8^24 h of incubation, they were processed for
immuno£uorescence.
Con£uent A10 cells were extracted with the bu¡er containing
20 mM Tris-Cl, pH 7.4, 125 mM sucrose, 0.05% Triton X-100,
2 mM EGTA, 1 mM PMSF, 100 WM leupeptin, 1 WM pepstatin
and 0^0.5 M KCl concentrations. The extracts were analysed by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and immunoblotting.
3. Results
3.1. MLCK-210 and MLCK-108 exhibit di¡erential extraction
properties
We examined the extraction of MLCK-210 and MLCK-108
from cultured cells using established procedures for cytoskel-
etal protein solubilisation. We used A10 rat aorta-derived
smooth muscle cells which express both MLCK-108 and
MLCK-210 (Fig. 2). Cells were extracted in bu¡ers containing
Triton X-100 and increasing concentrations of KCl and ana-
lysed for MLCK presence by immunoblotting. As shown in
Fig. 2, MLCK-108 was readily extracted into the soluble frac-
tion at a 100 mM KCl concentration, whereas most of the
MLCK-210 remained associated with the Triton-insoluble pel-
let fraction under these conditions. At 200 mM KCl, MLCK-
108 was detected exclusively in the soluble fraction, while
MLCK-210 was nearly equally distributed between soluble
and particulate fractions. Only at 300 mM KCl and higher,
MLCK-210 was localised mostly in the soluble fraction. These
results demonstrate that MLCK-210 and MLCK-108 di¡er in
their extraction properties and raise the possibility that the
unique N-terminal part of MLCK-210 contributes to its
stronger association with the Triton-insoluble particulate frac-
tion.
3.2. MLCK-210 and its unique amino-terminal segment have
actin binding activity
To directly assess interactions of MLCK-210 with the cy-
toskeletal elements, we conducted a co-sedimentation assay of
Fig. 1. Speci¢city of 2F4 monoclonal antibody. Fifteen Wg of chick-
en aorta extract was loaded per each lane, resolved by SDS-PAGE
and either stained for proteins (1) or blotted onto PVDF membrane
and probed with 2F4 monoclonal antibody (2) and polyclonal anti-
KRP antibodies (3). The position of puri¢ed turkey gizzard MLCK-
108 (20 ng) was also identi¢ed with anti-KRP antibodies (4). Posi-
tions of MLCK isoforms are marked as 210 and 108 and molecular
weight markers are shown on the left.
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F-actin and SMM ¢laments with MLCK-210 and N934. Fig.
3A shows that MLCK-210 does not sediment by itself, where-
as in the presence of F-actin or SMM, it distributes into the
pellet. Inclusion of chicken gizzard KRP in the mixture of
MLCK-210 and SMM results in attenuated binding of the
kinase to myosin ¢laments. Fig. 3B demonstrates that N934
binds to actin but its interaction with SMM was not signi¢-
cant when myosin was used at concentrations su⁄cient to
sediment MLCK-210. The presence of smooth muscle tropo-
myosin, caldesmon and Ca2-CaM in the incubation mixture
does not a¡ect N934 interaction with actin (data not shown).
Under low speed sedimentation conditions in which F-actin
does not pellet, N934 causes F-actin to sediment (Fig. 4A).
This is suggestive of formation of actin ¢lament aggregates.
Electron microscopic analysis of mixtures of N934 and F-ac-
tin revealed the presence of actin bundles (Fig. 4C), whereas
F-actin did not form the bundles in the absence of N934 (Fig.
4B). This suggests that the unique N-terminal tail region of
MLCK-210 contributes to the association of the kinase with
actin ¢laments and confers actin cross-linking properties to it.
3.3. MLCK-210 and its unique N-terminal segment localise
with the micro¢laments in cultured cells
MLCK-210 speci¢c 2F4 antibody stains micro¢lament bun-
dles in primary chicken embryo aortic cells (Fig. 5A),
although there appears to be a somewhat more heterogeneous
distribution of staining among cells compared to the actin
¢lament distribution (Fig. 5B). Transient transfection of
MLCK-210-GFP construct into HeLa cells produced a pat-
tern similar to the antibody staining, i.e. GFP £uorescence
was mainly associated with actin bundles (Fig. 5C,D). To
con¢rm the ability of the N-terminal domain of MLCK-210
to target ¢lamentous actin in living cell, a N934 construct
encoding N-terminal FLAG sequence was transiently trans-
fected into HeLa cells. Fig. 5E,F shows that accumulation of
N934 on the micro¢laments of transfected cells was observed.
These results suggest that the amino-terminal sequence of
MLCK-210 is involved in subcellular targeting of the enzyme
to the micro¢laments.
4. Discussion
The unique N-terminal domain of MLCK-210 which is not
found in MLCK-108 may harbour activities that provide for
the di¡erential features of MLCK isoforms in terms of cata-
Fig. 2. Di¡erential extraction of MLCK-210 and MLCK-108 from
A10 cells. The concentrations of KCl in extraction bu¡er are indi-
cated on the top of each panel. Triton-soluble supernatant fractions
(s) and insoluble particulate fractions (p) were analysed by immuno-
blotting using polyclonal anti-MLCK antiserum #859. Positions of
MLCK isoforms are marked as 210 and 108.
Fig. 3. Co-sedimentation assay of MLCK-210 and its N-terminal
segment with actin and myosin. A: A⁄nity-puri¢ed MLCK-210 was
incubated without (1) or with 2 WM F-actin (2), 4 WM F-actin (3),
0.6 WM SMM (4), 0.6 WM SMM and 18 WM KRP (5). The superna-
tants (S) and pellets (P) were immunoblotted and MLCK-210 was
visualised with #3528 speci¢c antibody. B: Recombinant N934 (3
WM) was incubated without (CONTR) and with 0.75, 1.5 or 3 WM
SMM (+MYOSIN) or with 3, 6 and 12 WM F-actin (+ACTIN).
The protein content of supernatants (S) and pellets (P) was assessed
by Coomassie staining. BSA, bovine serum albumin.
Fig. 4. N-terminal segment of MLCK-210 bundles F-actin in vitro.
(A) Ten WM F-actin was mixed with increasing concentrations of
N934 in the presence of 100 mm NaCl and subjected to low speed
centrifugation in the microfuge. Each point represents mean þ S.D.
of four experiments. (B) electron micrographs of F-actin and (C) of
F-actin-N934 mixture (7:1 = mol:mol). Scale bar, 1 Wm.
FEBS 23022 2-12-99
D.S. Kudryashov et al./FEBS Letters 463 (1999) 67^71 69
lytic activity or cytoskeletal interactions. In the study de-
scribed here, we examined these two hypotheses.
We designed a method to purify MLCK-210 from chicken
aorta and this allowed us for the ¢rst time to quantitatively
compare its speci¢c activity with that of MLCK-108 (see Sec-
tion 2). With the necessary corrections for the higher molec-
ular weight of MLCK-210, the activity of both isoforms was
similar. Hence, the unique tail of MLCK-210 is either not
involved in modulation of MLCK catalytic activity or addi-
tional modi¢cations such as tyrosine phosphorylation hypoth-
esised by Garcia et al. [14] are required for this to happen.
It is well documented that MLCK-108 binds actin and my-
osin in vitro and MLCK-108 antibodies as well as MLCK-108
expressed in transfected cells decorate micro¢laments [8,15^
17]. Similar features were demonstrated in our experiments
with regard to MLCK-210 (Fig. 3, 5A,B). We have shown
previously that the KRP domain of MLCK-108 contributes
to its interaction with myosin [13,18]. The results presented
here extend this to MLCK-210 (Fig. 3).
While our studies have been focused on smooth muscle cells
where MLCK-210 is associated with the micro¢laments,
others have reported additional localisation of a high molec-
ular weight MLCK in endothelial cells. Brie£y, Verin et al.
[19] and Garcia et al. [14] observed a punctate pattern of
MLCK staining not coincident with the micro¢laments and
similar punctation partially overlapping a ¢lamentous actin
network in thrombin-stimulated or diperoxovanadate-treated
cells. Perhaps, MLCK associates with the cellular structures
other than micro¢laments in these cells. The nature of poten-
tial alternative MLCK-210 intracellular targets would be of
great interest and additional studies might reveal their molec-
ular basis.
Cell extraction experiments demonstrated the stronger asso-
ciation of MLCK-210 than MLCK-108 with the detergent-
insoluble particulate fraction of A10 aortic smooth muscle
cells, suggesting that the amino-terminal sequence of
MLCK-210 provides additional linkages to the cytoskeletal
elements. The micro¢lament-associated distribution of
MLCK-210 established in this work (Fig. 5) indicates that
likely targets for the unique tail domain would be actin, my-
osin and macromolecules interacting with these proteins. In-
deed, we demonstrated that N934 binds F-actin in vitro and
colocalises with actin bundles in living cells (Fig. 3B, 4 and
5C,D).
The actin bundling activity of N934 suggests that there is an
extended actin binding site or, perhaps, several sites within the
MLCK-210 unique sequence. MLCK-108 was also shown to
bundle F-actin in vitro [20] by means of the two discrete actin
Fig. 5. Association of MLCK-210 and its N-terminal segment with micro¢laments in cultured cells. Primary chicken embryo aortic cells were
stained with 2F4 monoclonal antibody and FITC-labelled secondary antibody (A) and TRITC-phalloidin to visualise F-actin (B). HeLa cells
were transiently transfected with pEGFP-MLCK-210 construct (C,D) or pFLAG-N934 construct (E,F). (C) self-£uorescence of GFP, (D,F) ac-
tin visualised by TRITC-phalloidin, (E) anti-FLAG staining as revealed by FITC-labelled secondary antibody. Scale bar, 25 Wm.
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binding sites located in the N-terminus [21]. Because MLCK-
210 incorporates all of the MLCK-108 sequence, MLCK-210
is likely to have a superior actin binding and bundling ca-
pacity. This would be consistent with its lower extractability
from cultured cells.
The very C-terminal part of MLCK-210 unique sequence
contains two DXRXXL motifs similar to three such motifs
identi¢ed in the N-terminus of MLCK-108 and demonstrated
to a¡ect MLCK-108 interaction with micro¢laments [22]. The
distribution of precisely spaced DXRXXL motifs across the
border of the speci¢c and common parts of MLCK sequence
suggests the presence of a continuous actin binding region in
this area which is entirely used by MLCK-210 and partially
by MLCK-108. Altogether, our results indicate that MLCK-
210 may serve similar roles in cell function as MLCK-108 and
has an additional function as a more e⁄cient micro¢lament
network organiser due to the presence of extra actin binding
site(s) in its unique N-terminal sequence.
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